These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

439 related items for PubMed ID: 31801598

  • 1. Shisa3 brakes resistance to EGFR-TKIs in lung adenocarcinoma by suppressing cancer stem cell properties.
    Si J, Ma Y, Bi JW, Xiong Y, Lv C, Li S, Wu N, Yang Y.
    J Exp Clin Cancer Res; 2019 Dec 04; 38(1):481. PubMed ID: 31801598
    [Abstract] [Full Text] [Related]

  • 2. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
    Kang DH, Jung SS, Yeo MK, Lee DH, Yoo G, Cho SY, Oh IJ, Kim JO, Park HS, Chung C, Lee JE.
    BMC Cancer; 2020 Jun 18; 20(1):571. PubMed ID: 32552717
    [Abstract] [Full Text] [Related]

  • 3. MUSASHI-2 confers resistance to third-generation EGFR-tyrosine kinase inhibitor osimertinib in lung adenocarcinoma.
    Yiming R, Takeuchi Y, Nishimura T, Li M, Wang Y, Meguro-Horike M, Kohno T, Horike SI, Nakata A, Gotoh N.
    Cancer Sci; 2021 Sep 18; 112(9):3810-3821. PubMed ID: 34145929
    [Abstract] [Full Text] [Related]

  • 4. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS, Li M, Xu CX, Wang D.
    Cell Death Dis; 2018 Oct 31; 9(11):1111. PubMed ID: 30382076
    [Abstract] [Full Text] [Related]

  • 5. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
    Park HS, Lee DH, Kang DH, Yeo MK, Bae G, Lee D, Yoo G, Kim JO, Moon E, Huh YH, Lee SH, Jo EK, Cho SY, Lee JE, Chung C.
    Cancer Med; 2021 Feb 31; 10(4):1405-1417. PubMed ID: 33486901
    [Abstract] [Full Text] [Related]

  • 6. [STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma].
    Huang L, Hou M, Liu J, Li Y, Shen W, Zhou Q.
    Zhongguo Fei Ai Za Zhi; 2022 Nov 20; 25(11):771-781. PubMed ID: 36419390
    [Abstract] [Full Text] [Related]

  • 7. Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma.
    Sun J, Li G, Liu Y, Ma M, Song K, Li H, Zhu D, Tang X, Kong J, Yuan X.
    Neoplasia; 2020 Jan 20; 22(1):33-46. PubMed ID: 31765940
    [Abstract] [Full Text] [Related]

  • 8. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.
    Rong X, Liang Y, Han Q, Zhao Y, Jiang G, Zhang X, Lin X, Liu Y, Zhang Y, Han X, Zhang M, Luo Y, Li P, Wei L, Yan T, Wang E.
    J Thorac Oncol; 2019 Oct 20; 14(10):1766-1783. PubMed ID: 31228625
    [Abstract] [Full Text] [Related]

  • 9. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer.
    Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC, Shih JY.
    Oncotarget; 2015 Apr 30; 6(12):10415-31. PubMed ID: 25871388
    [Abstract] [Full Text] [Related]

  • 10. Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent Resistance.
    Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, Pitts S, Keswani M, Gao S, Nguyen KDP, Cowart J, Kirkali F, Wu C, Guha U.
    Cancer Res; 2021 Jun 01; 81(11):3051-3066. PubMed ID: 33727228
    [Abstract] [Full Text] [Related]

  • 11. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
    Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang Z, Ai B, Cao X, Guo T, Liao Y.
    J Exp Clin Cancer Res; 2019 Mar 15; 38(1):129. PubMed ID: 30876460
    [Abstract] [Full Text] [Related]

  • 12. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
    Fu S, Liu C, Huang Q, Fan S, Tang H, Fu X, Ai B, Liao Y, Chu Q.
    Oncol Rep; 2018 Mar 15; 39(3):1313-1321. PubMed ID: 29328407
    [Abstract] [Full Text] [Related]

  • 13. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.
    Kuo MH, Lee AC, Hsiao SH, Lin SE, Chiu YF, Yang LH, Yu CC, Chiou SH, Huang HN, Ko JC, Chou YT.
    Cancer Res; 2020 Oct 15; 80(20):4426-4438. PubMed ID: 32816907
    [Abstract] [Full Text] [Related]

  • 14. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
    Zhang Y, Chen B, Wang Y, Zhao Q, Wu W, Zhang P, Miao L, Sun S.
    Oncol Res; 2019 Jul 12; 27(7):751-761. PubMed ID: 30732676
    [Abstract] [Full Text] [Related]

  • 15. PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway.
    Li N, Zuo R, He Y, Gong W, Wang Y, Chen L, Luo Y, Zhang C, Liu Z, Chen P, Guo H.
    Cell Death Dis; 2024 Aug 01; 15(8):555. PubMed ID: 39090096
    [Abstract] [Full Text] [Related]

  • 16. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
    Dong S, Qu X, Li W, Zhong X, Li P, Yang S, Chen X, Shao M, Zhang L.
    J Hematol Oncol; 2015 Apr 29; 8():43. PubMed ID: 25925741
    [Abstract] [Full Text] [Related]

  • 17. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L, Liu J, Liu J, Chen X, Chang M, Li J, Zhou J, Bai C, Song Y.
    J Cancer Res Clin Oncol; 2019 Apr 29; 145(4):861-872. PubMed ID: 30661098
    [Abstract] [Full Text] [Related]

  • 18. Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis.
    Lou Y, Xu J, Zhang Y, Zhang W, Zhang X, Gu P, Zhong H, Wang H, Lu J, Han B.
    Cell Death Dis; 2021 Feb 10; 12(2):170. PubMed ID: 33568630
    [Abstract] [Full Text] [Related]

  • 19. mPRα mediates P4/Org OD02-0 to improve the sensitivity of lung adenocarcinoma to EGFR-TKIs via the EGFR-SRC-ERK1/2 pathway.
    Lu X, Guan A, Chen X, Xiao J, Xie M, Yang B, He S, You S, Li W, Chen Q.
    Mol Carcinog; 2020 Feb 10; 59(2):179-192. PubMed ID: 31777985
    [Abstract] [Full Text] [Related]

  • 20. Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Kita K, Fukuda K, Takahashi H, Tanimoto A, Nishiyama A, Arai S, Takeuchi S, Yamashita K, Ohtsubo K, Otani S, Yanagimura N, Suzuki C, Ikeda H, Tamura M, Matsumoto I, Yano S.
    Cancer Sci; 2019 Oct 10; 110(10):3215-3224. PubMed ID: 31432603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.